Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600210 | 0.88 | HPGD (0.51) | ALDH1A1HTTSMN1; SMN2HSD17B10PTGDR2 | |
| SCHEMBL4601189 | 0.87 | PTGDR2 (0.51) | ALDH1A1SMN1; SMN2HSD17B10TDP1PTGDR2 | |
| SCHEMBL16055509 | 0.87 | TDP1 (0.62) | ALDH1A1HTTSMN1; SMN2HSD17B10TDP1 | |
| SCHEMBL2772497 | 0.86 | SMN1; SMN2 (0.49) | ALDH1A1HTTSMN1; SMN2HSD17B10PTGDR2 | |
| SCHEMBL15912482 | 0.86 | PTGDR2 (0.53) | ALDH1A1HTTSMN1; SMN2HSD17B10PTGDR2 | |
| SCHEMBL3388835 | 0.85 | TSHR (0.62) | SMN1; SMN2HSD17B10PTGDR2HPGDNPSR1 | |
| SCHEMBL13064184 | 0.83 | PTGDR2 (0.71) | HTTSMN1; SMN2HSD17B10PTGDR2HPGD | |
| SCHEMBL16997485 | 0.83 | HSD17B10 (0.49) | ALDH1A1HTTSMN1; SMN2HSD17B10PTGDR2 | |
| SCHEMBL30361998 | 0.83 | ALDH1A1 (0.59) | ALDH1A1HTTSMN1; SMN2HSD17B10TDP1 | |
| SCHEMBL392403 | 0.83 | ALDH1A1 (0.59) | ALDH1A1HTTSMN1; SMN2HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021060281-A1 | PROSTAGLANDIN E2 RECEPTOR EP2/EP4 DUAL ANTAGONIST | ＡＧＣ株式会社 | 2021-04-01 | — | — | WO | disclosed |
| US-9776976-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3041826-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | Inception 2, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160194292-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2016-07-07 | — | — | US | disclosed |
| CN-105579440-A | Triazolone compounds and uses thereof | INCEPTION 2 INC | 2016-05-11 | — | — | CN | disclosed |
| WO-2015035059-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2012051708-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES, AND METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194292-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARD, PPARG | ALDH1A1 497/4885HTT 3704/4885SMN1; SMN2 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.